Whitehawk Therapeutics (WHWK) Equity Ratio (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Equity Ratio data on file, last reported at 0.91 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.91, down 3.64% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.91 (down 3.64% YoY), and the FY2025 annual result was 0.9, up 21.1% from the prior year.
• Equity Ratio rose to 0.91 in Q1 2026 per WHWK's latest filing, from 0.9 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.95 in Q2 2025 and troughed at 0.75 in Q4 2024.
• A 5-year average of 0.86 and a median of 0.86 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2024: Equity Ratio surged 301.68% in 2022, then dropped 10.78% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.86 in 2022, then declined by 7.59% to 0.79 in 2023, then decreased by 6.06% to 0.75 in 2024, then increased by 21.1% to 0.9 in 2025, then climbed by 1.04% to 0.91 in 2026.
• Business Quant data shows WHWK's Equity Ratio at 0.91 in Q1 2026, 0.9 in Q4 2025, and 0.94 in Q3 2025.